NasdaqGS:NTRABiotechs
Natera (NTRA) As Druckenmiller Backs Growth Story, Is The Valuation Already Priced In?
Natera (NTRA) is back on investor radar after Stanley Druckenmiller's family office made the stock its largest holding. This coincides with strong revenue growth, higher test volumes, and improving free cash flow.
See our latest analysis for Natera.
Natera’s recent news on clinical collaborations and higher test volumes sits alongside strong momentum in the stock. The 30 day share price return of 26.73% and 1 year total shareholder return of 104.36% point to building enthusiasm, while the...